Biologic Valves Are As Good As Mechanical Valves In Younger Patients, Study Shows
This article was originally published in The Gray Sheet
Executive Summary
Bioprosthetic replacement heart valves may be a reasonable alternative to mechanical valves in patients aged 50 to 69 years, according to a retrospective cohort analysis of 4,253 patients.
You may also be interested in...
Heart Valves in Europe: The Mix Will Change
According to "European Markets for Heart Valve Repair and Replacement Products," Medtech Insight's recent report, in the coming years growth in the heart valve industry will be somewhat flat in Europe-with a compound annual growth rate in the overall number of procedures of 1.6% between now and 2013. However, that number reflects a drop in the number of mechanical valves used, and a rise in tissue valves, which are enjoying increased uptake with each generation of technological improvements.
What’s Next At Dr Reddy’s: Biologics CDMO, Cell And Gene Therapy Push
Indian firms are getting their act together in areas like cell and gene therapy, with Dr Reddy’s aiming big and readying a facility alongside an alliance with a Chinese firm for a CAR-T therapy. The company is also doubling down in contract development and manufacturing, with an eye on opportunities in biologics.
Texas To Tokyo: Japan Darvias Approval Marks End Of Long Development Road
Solasia's arsenical drug darinaparsin has received its global-first approval in Japan, for PTCL, in a landmark for the Texan chemist who discovered it back in the 70s and paving the way for wider indications and Asian markets.